Plant Based Vaccines Market Scope And Analysis

Report Code : TIPRE00024327
Category : Life Sciences

No. of Pages : 150

Buy Now

Plant Based Vaccines Market Analysis, Size, and Growth (2024-2031)

Buy Now

Plant Based Vaccines Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 1.44 Billion
Market Size by 2031	US$ 3.96 Billion
Global CAGR (2023 - 2031)	13.5%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Vaccine Type Bacterial Vaccines Viral Vaccines Parasite Vaccines Plant-derived Virus-like particles By Source Tobacco Plant Maize Potato By Application Influenza Zika Virus Ebola Virus Poultry Disease
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	MEDICAGO INC British American Tobacco p l c ICON GENETICS GMBH CREATIVE BIOLABS INC iBio Inc LENIOBIO Lumen Bioscience Inc LEAF EXPRESSION SYSTEMS LTD ZYUS LIFE SCIENCES INC FRAUNHOFER CMB

Plant Based Vaccines Market News and Recent Developments

The Plant based vaccines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Plant based vaccines market are listed below:

Medicago and GlaxoSmithKline (GSK) declared that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID?19) caused by severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) in individuals 18 to 64 years of age. (Source: GlaxoSmithKline, Press Release, February 2022)
CEPI providing LenioBio with funding of up to US$2 million to provide preclinical proof-of-concept that a commercially available, plant-based, and cell-free technology can produce proteins to be used in vaccine trials for epidemic and pandemic threats in 20-40 days. Using LenioBio’s ALiCE technology, the ambition is to reduce the time required to manufacture vaccine proteins with “more traditional methods” like cell cultures. (Source: CEPI, Newsletter, May 2024)

Plant Based Vaccines Market Report Coverage and Deliverables

The “Plant Based Vaccines Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Plant based vaccines market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Plant based vaccines market trends as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST/Porter’s Five Forces and SWOT analysis
Plant based vaccines market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Plant based vaccines market
Detailed company profiles